Risultati per: Trattamento del cancro del colon retto metastatico

Questo è quello che abbiamo trovato per te

Assessment and Prognostic Value of Inflammatory Biomarkers in Patients With Colon Cancer—Reply

Jama Oncology

In Reply We thank McGovern et al for their interest in our analysis of inflammatory biomarkers and survival among patients with stage III colon cancer (CALGB/SWOG 80702). In this cohort study, we reported the levels of plasma inflammatory biomarkers, including interleukin 6 (IL-6), soluble tumor necrosis factor α receptor 2 (sTNF-αR2), and high-sensitivity C-reactive protein (CRP). We found that higher inflammation after diagnosis was significantly associated with worse survival among patients with stage III colon cancer.

Leggi →
Agosto 2023

Assessment and Prognostic Value of Inflammatory Biomarkers in Patients With Colon Cancer

Jama Oncology

To the Editor We read the cohort study assessing the association of inflammatory biomarkers with survival among patients with stage III colon cancer by Cheng et al with some interest. This post hoc analysis of 1494 patients who underwent potentially curative surgical resection and adjuvant chemotherapy for TNM stage III colon cancer showed an association between inflammatory status, recurrence, and mortality. In the context of a multicenter, double-blind, phase 3, adjuvant chemotherapy trial of anti-inflammatory agents, inflammatory status was measured using interleukin 6 (IL-6), tumor necrosis factor (TNF) α receptor 2 (sTNF-αR2), and high-sensitivity C-reactive protein (CRP) levels. The values of the objective biomarkers reported in this large, well-designed cohort study allow comparison with previous studies.

Leggi →
Agosto 2023
← Pagina precedente
Pagina successiva →